(Q33709854)

28 July 2017

1 reference

title

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates (English)

1 reference

28 July 2017

0 references

Coagulation factor VIII

0 references

hemophilia A

0 references

author name string

Scharrer I

series ordinal

1

1 reference

28 July 2017

Bray GL

series ordinal

2

1 reference

28 July 2017

Neutzling O

series ordinal

3

1 reference

28 July 2017

publication date

1 May 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

5

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

145-154

1 reference

Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Acquired circulating anticoagulants in hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Inhibitors to monoclonal antibody purified factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Molecular etiology of factor VIII deficiency in hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Possible linkage between the major histocompatibility complex and the immune response to factor VIII in classic haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00300.X

10.1046/J.1365-2516.1999.00300.X

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference